Rilotumumab clinical trials
Also written AMG 102.
How each study uses rilotumumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 6
Amgen (7) · NantBioScience, Inc. (1) · UNICANCER (1) · Gynecologic Oncology Group (1) · Ahmad Tarhini (1) · Katy Peters (1) · NantCell, Inc. (1) · SWOG Cancer Research Network (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses rilotumumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung CancerTerminatedPhase 1/2NantCell, Inc.NCT00791154Written as AMG 102How we know
- Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)CompletedPhase 1/2NantBioScience, Inc.NCT00788957Written as RilotumumabHow we know
- MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal AdenocarcinomaCompletedPhase 2UNICANCERNCT01443065Written as AMG102How we know
- Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesTerminatedPhase 2/3SWOG Cancer Research NetworkNCT02926638Written as RilotumumabHow we know
- Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedPhase 2Gynecologic Oncology GroupNCT01039207Written as RilotumumabHow we know
- AMG 102 and Erlotinib for Advanced Non-Small Cell Lung CancerCompletedPhase 1/2Ahmad TarhiniNCT01233687Written as AMG 102 and erlotinibHow we know
- A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric CancerTerminatedPhase 3AmgenNCT02137343Written as RilotumumabHow we know
- Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJCompletedPhase 1AmgenNCT01791374Written as RilotumumabHow we know
- First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) AdenocarcinomaTerminatedPhase 3AmgenNCT01697072Written as RilotumumabHow we know
- AMG 102 and Avastin for Recurrent Malignant GliomaCompletedPhase 2Katy PetersNCT01113398Written as AMG 102How we know
- A Phase II Study to Treat Advanced Malignant GliomaCompletedPhase 2AmgenNCT00427440Written as AMG 102 at 20 mg/kgHow we know
- A Phase II Study to Treat Subjects With Advanced Renal Cell CarcinomaCompletedPhase 2AmgenNCT00422019Written as AMG 102 at 10 mg/kgHow we know
- AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate CancerCompletedPhase 1/2AmgenNCT00770848Written as AMG 102How we know
- AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction CancerCompletedPhase 1/2AmgenNCT00719550Written as AMG 102How we know
- AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural MesotheliomaWithdrawnPhase 2National Cancer Institute (NCI)NCT01105390Written as rilotumumabHow we know
Codes
What other systems call rilotumumab · ClinicalTrials.gg INT005183
- MeSH (NLM) C524459rilotumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 51WEW898IJRILOTUMUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7334301RilotumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C67079RilotumumabOne source FDA
- DrugBank DB11972One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C524459 | rilotumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 51WEW898IJ | RILOTUMUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7334301 | Rilotumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C67079 | Rilotumumab | One source FDA |
| DrugBank | DB11972 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.